All Updates

All Updates

icon
Filter
M&A
Listing
BenevolentAI completes SPAC deal; debuts on Euronext Amsterdam
AI Drug Discovery
Apr 25, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Apr 25, 2022

BenevolentAI completes SPAC deal; debuts on Euronext Amsterdam

M&A
Listing

<ul><li>London-based AI drug discovery company BenevolentAI has completed its previously announced EUR 1.5 billion (USD 1.6 billion) special purpose acquisition company (SPAC) deal —reportedly the largest European SPAC transaction ever. It started trading its common shares on the Euronext Amsterdam Market under the ticker symbol “BAI” effective from April 25, 2022.</ul>

  • The combined entity, following the completion of the deal on April 22, 2022, raised gross proceeds of EUR 225 million (USD 242 million). It will be used to fuel its internal clinical pipeline of over 20 drug programs, to complete phase 1/2 clinical trials of two of its candidates by 2023, and further develop its AI drug discovery platform.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.